These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25245469)

  • 1. DART-bid: dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily: high local control in early stage (I/II) non-small-cell lung cancer.
    Zehentmayr F; Wurstbauer K; Deutschmann H; Fussl C; Kopp P; Dagn K; Fastner G; Porsch P; Studnicka M; Sedlmayer F
    Strahlenther Onkol; 2015 Mar; 191(3):256-63. PubMed ID: 25245469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)--a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume.
    Wurstbauer K; Deutschmann H; Dagn K; Kopp P; Zehentmayr F; Lamprecht B; Porsch P; Wegleitner B; Studnicka M; Sedlmayer F
    Radiat Oncol; 2013 Mar; 8():49. PubMed ID: 23497555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DART-bid for loco-regionally advanced NSCLC : Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints.
    Wurstbauer K; Zehentmayr F; Deutschmann H; Dagn K; Exeli AK; Kopp P; Porsch P; Maurer B; Studnicka M; Sedlmayer F
    Strahlenther Onkol; 2017 Apr; 193(4):315-323. PubMed ID: 28116446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).
    Zehentmayr F; Söhn M; Exeli AK; Wurstbauer K; Tröller A; Deutschmann H; Fastner G; Fussl C; Steininger P; Kranzinger M; Belka C; Studnicka M; Sedlmayer F
    Radiat Oncol; 2015 May; 10():121. PubMed ID: 26018527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results.
    King SC; Acker JC; Kussin PS; Marks LB; Weeks KJ; Leopold KA
    Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):593-9. PubMed ID: 8948343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
    Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience.
    Sibley GS; Jamieson TA; Marks LB; Anscher MS; Prosnitz LR
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):149-54. PubMed ID: 9422571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer.
    Maguire PD; Marks LB; Sibley GS; Herndon JE; Clough RW; Light KL; Hernando ML; Antoine PA; Anscher MS
    J Clin Oncol; 2001 Feb; 19(3):705-11. PubMed ID: 11157021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-small cell lung cancer in stages I-IIIB: Long-term results of definitive radiotherapy with doses ≥ 80 Gy in standard fractionation.
    Wurstbauer K; Weise H; Deutschmann H; Kopp P; Merz F; Studnicka M; Nairz O; Sedlmayer F
    Strahlenther Onkol; 2010 Oct; 186(10):551-7. PubMed ID: 20936459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer.
    Chang JY; Komaki R; Wen HY; De Gracia B; Bluett JB; McAleer MF; Swisher SG; Gillin M; Mohan R; Cox JD
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1350-7. PubMed ID: 21251767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac Dose and Survival After Stereotactic Body Radiotherapy for Early-stage Non-Small-cell Lung Cancer.
    Tembhekar AR; Wright CL; Daly ME
    Clin Lung Cancer; 2017 May; 18(3):293-298. PubMed ID: 28089158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperfractionated accelerated radiation therapy for non-small cell lung cancer: clinical phase I/II trial.
    Fu XL; Jiang GL; Wang LJ; Qian H; Fu S; Yie M; Kong FM; Zhao S; He SQ; Liu TF
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):545-52. PubMed ID: 9336130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.
    Salazar OM; Sandhu TS; Lattin PB; Chang JH; Lee CK; Groshko GA; Lattin CJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):707-15. PubMed ID: 18455322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
    Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
    Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiation therapy for medically inoperable early-stage lung cancer: Tata Memorial Hospital perspective and practice recommendations.
    Agarwal JP; Pilar A; Mummudi N; Gupta M; Laskar SG; Pathak RS; Tibdewal AR; Kinhikar R; Ghadi Y; Tandon S; Purandare N; Prabhash K; Patil V
    Indian J Cancer; 2020; 57(1):18-24. PubMed ID: 31929233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of high-dose thoracic irradiation incorporating beam's eye view display in non-small cell lung cancer: a retrospective multivariate analysis.
    Hazuka MB; Turrisi AT; Lutz ST; Martel MK; Ten Haken RK; Strawderman M; Borema PL; Lichter AS
    Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):273-84. PubMed ID: 8407401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis.
    Urbanic JJ; Turrisi AT; Sharma AK; Silvestri GA; Williams TE; Vanek KN; Sherman CA
    J Thorac Oncol; 2006 Feb; 1(2):112-9. PubMed ID: 17409839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonresected non-small-cell lung cancer in Stages I through IIIB: accelerated, twice-daily, high-dose radiotherapy--a prospective Phase I/II trial with long-term follow-up.
    Wurstbauer K; Deutschmann H; Kopp P; Kranzinger M; Merz F; Nairz O; Studnicka M; Sedlmayer F
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1345-51. PubMed ID: 19910140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Single- and Three-fraction Schedules of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-Small-cell Lung Cancer.
    Ma SJ; Serra LM; Syed YA; Hermann GM; Gomez-Suescun JA; Singh AK
    Clin Lung Cancer; 2018 Mar; 19(2):e235-e240. PubMed ID: 29153897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.